---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-086878"
form_type: "8-K"
ticker: null
cik: "0001673772"
company_name: "RAPT Therapeutics, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:17:43.836750+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# GSK completes acquisition of RAPT Therapeutics for $58.00 per share; RAPT to be delisted

## Summary
- Offer price of $58.00 per share; approx. 93.36% of outstanding shares validly tendered.
- Merger completed March 3, 2026 under DGCL Section 251(h); RAPT now a wholly owned GSK subsidiary.
- Shares delisted from Nasdaq; Form 25 and Form 15 to be filed to deregister and suspend SEC reporting.
- Board replaced: all prior directors resigned; Kevin Ryan and Justin Huang appointed as directors; new officers named.
- Outstanding equity awards converted to cash consideration per Merger Agreement terms.

## SEC filing metadata
- accession: 0001193125-26-086878
- form_type: 8-K
- cik: 0001673772
- company_name: RAPT Therapeutics, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1673772/000119312526086878/0001193125-26-086878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1673772/000119312526086878/d69681d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-086878
- JSON: https://secwatch.observer/filing/0001193125-26-086878.json
- Plain text: https://secwatch.observer/filing/0001193125-26-086878.txt

## Source-grounded claims
- claim_id: 15f1af15edd40d36cfe02a3f9c6c4bd167c789c7
  claim: RAPT Therapeutics, Inc.: Amended and restated the company's bylaws at the effective time of the merger.
  evidence_excerpt: Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety
  evidence_url: https://www.sec.gov/Archives/edgar/data/1673772/000119312526086878/0001193125-26-086878-index.htm
- claim_id: b8fe0d0f223b7be28aedc17cead55c04c5e8b885
  claim: RAPT Therapeutics, Inc.: Amended and restated the company's certificate of incorporation at the effective time of the merger.
  evidence_excerpt: Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety
  evidence_url: https://www.sec.gov/Archives/edgar/data/1673772/000119312526086878/0001193125-26-086878-index.htm
- claim_id: f6efb0bc93548986f3958abbc2fb0479a2e80b67
  claim: RAPT Therapeutics, Inc. underwent a change of control involving GlaxoSmithKline LLC for $58.00 per Share in cash (closed 2026-03-03).
  evidence_excerpt: a cash tender offer (the “ Offer ”) to purchase all of the outstanding shares of common stock of the Company, par value $0.0001 per share (the “ Shares ”), at a price of $58.00 per Share (the “ Offer Price ”), in cash, without interest and subject to any applicable withholding of taxes. The Offer expired at one minute following 11:59 P.M., Eastern Time,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1673772/000119312526086878/0001193125-26-086878-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.